Stempeucel-OA US patent marks an important intellectual-property milestone for Stempeutics Research and its cell-based approach to knee osteoarthritis. The therapy uses pooled, allogeneic, bone marrow-derived mesenchymal stromal cells (MSCs) and is being developed as a regenerative medicine approach for patients with knee osteoarthritis.
Stempeucel has been studied in randomized Phase 3 clinical research, while Stempeutics says its Stempeucel platform has received patent protection in multiple countries, including the United States.
Quick Summary
Stempeucel-OA is a cell-based therapy developed by Stempeutics Research for knee osteoarthritis. It uses 25 million cultured, pooled bone marrow-derived mesenchymal stromal cells and is administered through an intra-articular approach with hyaluronic acid. The technology has received US patent protection, adding to Stempeutics’ global intellectual-property portfolio.
What Is Stempeucel-OA?
Stempeucel-OA is an allogeneic cell therapy based on cultured and expanded mesenchymal stromal cells derived from the bone marrow of healthy adult donors.
According to Stempeutics, its Stempeucel platform uses a proprietary pooling technology in which cells obtained from qualified healthy donors are pooled to develop an off-the-shelf cell therapy product.
For knee osteoarthritis, the therapy has been studied as a single intra-articular injection containing 25 million bone marrow-derived mesenchymal stromal cells, followed by hyaluronic acid administration.
Key Features of Stempeucel-OA
| Feature | Details |
|---|---|
| Therapy type | Allogeneic cell therapy |
| Cell source | Adult human bone marrow |
| Cell type | Mesenchymal stromal cells (MSCs) |
| Cell dose studied | 25 million cells |
| Administration | Intra-articular injection |
| Additional treatment | Hyaluronic acid |
| Main indication | Knee osteoarthritis |
| Clinical evidence | Randomized Phase 3 study |
| Developer | Stempeutics Research |
What Does the US Patent Cover?
Stempeutics has built a broad patent portfolio around its Stempeucel technology. The company’s official information states that the Stempeucel patent estate includes process, MSC-pooling, use and process-improvement patents, with grants in multiple countries including the US.
A patent application relating specifically to combination therapy using mesenchymal stromal cells and hyaluronic acid for osteoarthritis describes ultrasound-guided intra-articular administration of pooled mesenchymal stromal cells together with mid-molecular-weight hyaluronic acid.
The Approach Involves
- Pooled mesenchymal stromal cells derived from adult bone marrow
- Ultrasound-guided intra-articular administration
- Hyaluronic acid as part of the treatment approach
- Assessment of biological markers associated with inflammation and osteoarthritis progression
The patent should be understood as intellectual-property protection for a defined technology or treatment approach, rather than proof that the therapy is approved for osteoarthritis in the United States.
How Does Stempeucel-OA Work?
Mesenchymal stromal cells are being investigated in regenerative medicine because of their immunomodulatory and anti-inflammatory properties.
In osteoarthritis, the goal of cell-based approaches is to influence the joint environment and potentially reduce inflammatory activity, pain and functional limitations.
Stempeutics describes Stempeucel as having anti-inflammatory effects and potential chondrogenic activity.
However, mechanisms observed in laboratory and clinical research should not be interpreted as a guarantee that every patient will experience cartilage regeneration or disease reversal.
What Does the Phase 3 Evidence Show?
A randomized, double-blind, multicenter, placebo-controlled Phase 3 study evaluated Stempeucel in 146 patients with Grade 2 and Grade 3 knee osteoarthritis.
Participants received either 25 million bone marrow-derived MSCs or placebo, followed by hyaluronic acid. The study assessed WOMAC scores, pain, stiffness, physical function and MRI-based cartilage measures.
Reported Findings
The study reported:
- Significant improvement in overall WOMAC scores at 6 and 12 months.
- Improvements in WOMAC pain, stiffness and physical-function scores.
- Improvements in visual analogue scale pain scores.
- No worsening of deep cartilage in the assessed medial femorotibial compartment at 12 months in the MSC group.
- Five adverse events considered possibly or probably related to the study treatment, involving injection-site swelling and pain that improved within a few days.
A later publication reported two-year efficacy and safety outcomes from the Phase 3 study, further extending the available follow-up evidence.
Is Stempeucel-OA Approved in India?
Yes. Stempeutics states that its knee osteoarthritis Stempeucel product has received marketing authorization in India. Its current website describes the OA product as commercially approved.
Cipla announced the launch of Ciplostem for Grade II and III knee osteoarthritis in December 2025, describing it as a single-dose intra-articular allogeneic mesenchymal stromal cell therapy containing 25 million cells and administered with hyaluronic acid.
Stempeutics also identifies StemOne as its knee osteoarthritis product marketed through its agreement with Alkem Laboratories.
India Market Information
| Item | Information |
| Developer | Stempeutics Research |
| Indication | Knee osteoarthritis |
| Cell type | Bone marrow-derived mesenchymal stromal cells |
| Dose | 25 million cells |
| Administration | Intra-articular |
| Cipla brand | Ciplostem |
| Alkem brand | StemOne |
Does the US Patent Mean Stempeucel-OA Is Approved in the USA?
No.
A US patent and regulatory approval are two different things.
A patent provides intellectual-property protection for an invention or claimed technology. Regulatory approval, on the other hand, determines whether a medical product can legally be marketed for a particular indication in a country.
Current scientific literature notes that no cell therapy product for osteoarthritis had received approval in the US, UK or European Union at the time of the cited review.
Therefore, the Stempeucel-OA US patent should not be described as US FDA approval.
Why Is This Patent Important?
The patent milestone is significant for several reasons.
1. Strengthens Intellectual Property
Patent protection can help protect proprietary technology from direct imitation and support long-term commercialization strategies.
2. Supports Stem Cell Technology Development
Stempeutics has developed a broader patent portfolio around pooled allogeneic MSC technology. The company states that its Stempeucel patent estate covers process, pooling and therapeutic-use technologies.
3. Adds Global Visibility
US patent protection can be strategically important for biotechnology companies developing technologies intended for international markets.
4. Highlights the Growth of Regenerative Medicine
Stempeucel-OA is part of a broader movement toward investigating cell-based therapies for chronic musculoskeletal diseases.
Why Is Stempeucel-OA Relevant to Regenerative Medicine?
Traditional osteoarthritis management commonly focuses on reducing pain, improving mobility and maintaining joint function.
Cell-based therapies are being investigated as potential approaches that may influence the biological environment of the damaged joint.
Stempeucel is particularly notable because it uses pooled, allogeneic, culture-expanded bone marrow-derived MSCs, allowing development of an off-the-shelf product rather than requiring cells to be collected and expanded separately for every patient.
Important Facts at a Glance
| Question | Answer |
| What is Stempeucel-OA? | A bone marrow-derived MSC-based cell therapy for knee OA |
| Who developed it? | Stempeutics Research |
| What cells are used? | Adult human bone marrow-derived mesenchymal stromal cells |
| What is the studied dose? | 25 million cells |
| How is it administered? | Intra-articular injection |
| What is it combined with? | Hyaluronic acid |
| What clinical stage has been studied? | Phase 3 |
| Is it approved in India? | Yes, for knee osteoarthritis |
| Is a US patent the same as FDA approval? | No |
| Is it relevant to regenerative medicine? | Yes |
What Should Pharmacy Students Know About This Development?
For B.Pharm, M.Pharm, Pharm.D and pharmacy competitive-exam aspirants, Stempeucel-OA is a useful example of how biotechnology, cell therapy, regulatory science and intellectual property intersect in modern pharmaceutical development.
Important concepts to understand include:
- Mesenchymal stromal cells
- Allogeneic cell therapy
- Bone marrow-derived cells
- Intra-articular drug administration
- Osteoarthritis
- Regenerative medicine
- Phase 3 clinical trials
- Hyaluronic acid
- Intellectual-property protection
- Patent versus regulatory approval
These concepts can also be useful for pharmacy students studying pharmacology, biotechnology, clinical research, novel drug delivery systems and regulatory affairs.
Latest Status of Stempeucel-OA
Stempeutics currently identifies its knee osteoarthritis Stempeucel product as commercially approved in India. Its broader Stempeucel platform also has patent protection across several countries.
The company continues to position Stempeucel as a platform technology based on pooled allogeneic mesenchymal stromal cells.
Frequently Asked Questions
1. What is Stempeucel-OA?
Stempeucel-OA is a cell-based therapy developed by Stempeutics Research for knee osteoarthritis using pooled, allogeneic, bone marrow-derived mesenchymal stromal cells.
2. What is the Stempeucel-OA US patent?
It refers to US patent protection associated with Stempeutics’ Stempeucel technology and its therapeutic applications. The company’s patent portfolio includes process, pooling and use-related patents.
3. How many cells are used in Stempeucel-OA?
The Phase 3 knee osteoarthritis study used a dose of 25 million bone marrow-derived mesenchymal stromal cells.
4. How is Stempeucel-OA administered?
The treatment studied for knee osteoarthritis involves an intra-articular injection, with hyaluronic acid administered as part of the treatment protocol.
5. Is Stempeucel-OA approved in India?
Yes. Stempeutics states that its Stempeucel product for knee osteoarthritis has received commercial approval in India.
6. Is Stempeucel-OA FDA approved in the USA?
A US patent does not mean FDA approval. Patent protection and regulatory authorization are separate processes.
7. Which companies market the OA product in India?
Stempeutics identifies Alkem Laboratories as its marketing partner for the knee osteoarthritis product, marketed as StemOne. Cipla has also launched Ciplostem for knee osteoarthritis.
8. Is Stempeucel-OA a stem cell treatment for osteoarthritis?
Yes. It is an allogeneic mesenchymal stromal cell-based therapy developed for knee osteoarthritis and studied in randomized clinical trials.
Conclusion
The Stempeucel-OA US patent is an important intellectual-property development for Stempeutics Research and its mesenchymal stromal cell technology for knee osteoarthritis. The therapy uses pooled, allogeneic bone marrow-derived MSCs and has been evaluated in a randomized Phase 3 clinical study.
Stempeutics has also established a commercial presence for its knee osteoarthritis product in India, while the company continues to develop its broader regenerative medicine platform.
For pharmacy students and healthcare professionals, the development is particularly relevant because it brings together stem cell technology, clinical research, regenerative medicine, regulatory approval and pharmaceutical intellectual property.
Recommended Products
